J&J says ICOTYDE met primary endpoint in Phase 3 psoriatic arthritis study

Johnson & Johnson announced its Phase 3 study of the oral peptide ICOTYDE (icotrokinra) met its primary endpoint in biologic-naïve adults with active psoriatic arthritis. At Week 16, 58% of treated patients achieved an ACR20 response versus 41% on placebo, with no new safety signals.

Detected & updated continuously · Source: Nebula